GH axis
Tesamorelin
TH9507
Stabilized GHRH analog · Visceral adipose research
A synthetic analog of human GHRH(1-44) stabilized by N-terminal trans-3-hexenoic acid. Approved as Egrifta for HIV-associated lipodystrophy and widely studied in visceral adipose tissue research.
For laboratory research use only. Not for human or animal consumption, not a drug, food, cosmetic, or supplement. By adding to cart, the researcher affirms compliance with all applicable regulations.
Vial size
Research price
$79
SKU ABL-TES-2
Ships cold-chain · Lot ABL-TES-2601 · Checkout secured by Waave
Specifications
Tesamorelin is a stabilized 44-amino-acid analog of human growth hormone releasing hormone. A trans-3-hexenoic acid modification at the N-terminus confers resistance to enzymatic degradation and extends circulating half-life in published pharmacokinetic studies.
Tesamorelin is FDA-approved as Egrifta® for HIV-associated lipodystrophy, where clinical literature has documented reductions in visceral adipose tissue. In broader research contexts, the peptide is studied as a tool for examining GH/IGF-1 axis modulation and ectopic fat deposition.
Supplied exclusively as a research reagent.
Related research tools